Valentine Turpin

Dr. Valentine Turpin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NRNathaniel L. Ritz
Nathaniel L. Ritz
MBMarta Brocka
Marta Brocka
MBMary I. Butler
Mary I. Butler
CCCaitlin S. M. Cowan
Caitlin S. M. Cowan
CBCamila Barrera-Bugueño
Camila Barrera-Bugueño
JCJohn F Cryan
John F Cryan
Social anxiety disorder (SAD) is a crippling psychiatric disorder characterized by intense fear or anxiety in social situations and their avoidance. However, the underlying biology of SAD is unclear and better treatments are needed. Recently, the gut microbiota has emerged as a key regulator of both brain and behaviour, especially those related to social function. Moreover, increasing data supports a role for immune function and oxytocin signalling in social responses. To investigate whether the gut microbiota plays a causal role in modulating behaviours relevant to SAD, we transplanted the microbiota from SAD patients, which was identified by 16S rRNA sequencing to be of a differential composition compared to healthy controls, to mice. Although the mice that received the SAD microbiota had normal behaviours across a battery of tests designed to assess depression and general anxiety-like behaviours, they had a specific heightened sensitivity to social fear, a model of SAD. This distinct heightened social fear response was coupled with changes in central and peripheral immune function and oxytocin expression in the bed nucleus of the stria terminalis. This work demonstrates an interkingdom basis for social fear responses and posits the microbiome as a potential therapeutic target for SAD.

Verified
Journal Article
Open access
PDF file
MTMathieu Thabault
Mathieu Thabault
VTValentine Turpin
Valentine Turpin
AMAlexandre Maisterrena
Alexandre Maisterrena
Mohamed JABERMohamed JABER
Mohamed JABER
MEMatthieu Egloff
Matthieu Egloff
LAURIE GALVANLAURIE GALVAN
LAURIE GALVAN
Autism spectrum disorders (ASD) are complex conditions that stem from a combination of genetic, epigenetic and environmental influences during early pre- and postnatal childhood. The review focuses on the cerebellum and the striatum, two structures involved in motor, sensory, cognitive and social functions altered in ASD. We summarize clinical and fundamental studies highlighting the importance of these two structures in ASD. We further discuss the relation between cellular and molecular alterations with the observed behavior at the social, cognitive, motor and gait levels. Functional correlates regarding neuronal activity are also detailed wherever possible, and sexual dimorphism is explored pointing to the need to apprehend ASD in both sexes, as findings can be dramatically different at both quantitative and qualitative levels. The review focuses also on a set of three recent papers from our laboratory where we explored motor and gait function in various genetic and environmental ASD animal models. We report that motor and gait behaviors can constitute an early and quantitative window to the disease, as they often correlate with the severity of social impairments and loss of cerebellar Purkinje cells. The review ends with suggestions as to the main obstacles that need to be surpassed before an appropriate management of the disease can be proposed.


7 April 2026
Verified
Thesis
Closed access
VTValentine Turpin
Valentine Turpin
Les troubles du spectre autistique (TSA) sont des troubles neurodéveloppementaux, touchant 3,7 hommes pour 1 femme en France, qui se traduisent principalement par des déficits persistants dans les comportements sociaux ainsi que par des comportements, intérêts et activités restreints et répétés. L’exposition à des facteurs environnementaux, notamment durant la période périnatale, serait majoritairement impliquée dans l’étiologie des TSA. On retrouve parmi ces facteurs, des composés pharmacologiques comme l’acide valproïque (VPA) (Dépakine®), dont l’exposition in utero augmente la probabilité de développer des TSA. Le cervelet, par ses fonctions cognitives et motrices, représente l’une des structures les plus impliquées dans la physiopathologie des TSA par des modifications anatomiques, cellulaires et moléculaires chez des patients et modèles animaux de TSA. Une supplémentation en acides gras polyinsaturés à longue chaîne n-3 (AGPI-LC n-3) sur plusieurs mois permet de réduire les symptômes de TSA chez des enfants. L’objectif de cette thèse a donc été de déterminer si une alimentation supplémentée en AGPI-LC n-3 en période périnatale pouvait protéger des symptômes de TSA induits par une exposition in utero au VPA chez la souris. Nous avons réalisé une étude longitudinale portant sur l’évolution des symptômes sociaux et moteurs ainsi que sur les corrélats cellulaires et moléculaires cérébelleux chez des souris mâles et femelles. Ces travaux ont permis de mettre en évidence qu’une alimentation équilibrée en AGPI n-3 et n-6 permet de protéger contre l’apparition de symptômes comportementaux, la perte de neurones cérébelleux et la dysbiose du microbiote intestinal.

9 March 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
VTValentine Turpin
Valentine Turpin
CKCharles Kakilla
Charles Kakilla
Jessica FooteJessica Foote
Jessica Foote
OCOliver Chen
Oliver Chen
WHWilliam Hooper
William Hooper
AWAmy Wescott
Amy Wescott
Urinary tract infections (UTIs) impose a substantial burden on women’s health, and probiotics have emerged as an alternative strategy to support urogenital wellbeing. This study evaluated the antimicrobial properties of Limosilactobacillus reuteri 3613-1 and its ability to improve UTI outcomes in women with a history of recurrent uncomplicated UTIs. In vitro assays demonstrated that L. reuteri 3613-1 inhibited the growth of Escherichia coli isolates and proved superior inhibition of Gardnerella vaginalis and Candida albicans compared with a comparator L. reuteri strain, supported by confirmed reuterin production and genomic profiling. A randomized, double-blind, placebo-controlled clinical trial (n = 130) assessed daily supplementation with L. reuteri 3613-1 for 24 weeks. While the proportion, frequency, and intensity of confirmed UTIs did not differ significantly between groups, L. reuteri 3613-1 delayed the onset of the first UTI, reaching significance in participants with suspected while unconfirmed UTIs. Vaginal pH and vaginal microbiome composition remained stable and comparable between groups across the intervention. The product was safe and well tolerated. Overall, L. reuteri 3613-1 shows promise as a probiotic candidate with antimicrobial activity and potential to delay symptom onset in women susceptible to recurrent UTIs, warranting further investigation in larger studies.